Preclinical and experimental research in thoracic tumors (PReTT)
PRINCIPAL INVESTIGATORS
- Ivan Macía Vidueira
- Amaia Ojanguren Arranz
CLINICAL RESEARCHERS
- Maria Jové Casulleras
- Ramon Palmero Sanchez
- Noelia Vilariño Quintela
POSTDOCTORAL RESEARCHERS
- David Cordero Romera
- Mireia Gausachs Romero
- Sara Hijazo Pechero
PREDOCTORAL RESEARCHERS
- Ania Alay Badosa
- Lidia Collado Rodriguez
- Mabel Cruz Rodriguez
- Silvia Plans Marin
- Iswarya Sreeram
- Ming Tang
SCIENTIFIC SUPPORT
- Maria Ajenjo Bauza
- David Barroso Barquilla
- Felipe Jimenez Hernandez
- Didac Nestor Palau Gallinat
MANAGEMENT SUPPORT
- Joaquim Moreno Caceres
- Anna Ruiz Mitjana
Cancer
Oncobell
Scientific production
30
PAPERS
Average IF: 15,01
7
LED PAPERS
Average IF: 3,46
11 PUBLICATIONS IN FIRST DECILE
23 PUBLICATIONS IN FIRST QUARTILE
22 PUBLICATIONS IN PUBLIC ACCESS
Selected publications
- Alay,A;Marin,R;Aliagas,E;Gausachs,M;Ruiz Gil,M;Macia,I;Ojanguren,A et al, Single-cell RNA-sequencing as a potential approach for studying intratumor heterogeneity in pleural mesothelioma, Lung Cancer, 2025;207108679-108679, doi:10.1016/j.lungcan.2025.108679
- Cruz Rodríguez,M;Chevet,E;Muñoz Pinedo,C, Glucose sensing and the unfolded protein response., FEBS J, 2025;292(14):3581-3595, doi:10.1111/febs.70113
- Déniz,C;Marcè,J;Macia,I;Rivas,F;Muñoz,A;Paradela,M;García,S et al, Artificial intelligence in thoracic surgery consultations: evaluating the concordance between a large language model and expert clinical decisions., Front Digit Health, 2025;71633278-1633278, doi:10.3389/fdgth.2025.1633278
- Heymach,JV;Ruiter,G;Ahn,MJ;Girard,N;Smit,EF;Planchard,D;Wu,YL et al, Zongertinib in Previously Treated HER2-Mutant Non-Small-Cell Lung Cancer., N Engl J Med, 2025;392(23):2321-2333, doi:10.1056/NEJMoa2503704
- Riely,GJ;Ahn,MJ;Clarke,JM;Dagogo Jack,I;Esper,R;Felip,E;Gelsomino,F et al, Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC?A Brief Report., J. Thorac. Oncol., 2025;20(10):1538-1547, doi:10.1016/j.jtho.2025.05.023,
Research highlights
PROJECTS
1 Granted competitive project
11 Ongoing competitive projects
15 Started clinical trials
62 Ongoing clinical trials
PUBLISHED WORKS
1 Clinical Guideline
1 Thesis
NETWORKS
AGAUR SGR – GRC 2021
RED2022-1343
Selected projects
- PI24/00702. Exploración de la dinámica de la caquexia asociada a cáncer, el perfil tumoral y la carga de enfermedad en pacientes con cáncer de pulmón de célula no pequeña. Instituto de Salud Carlos III (ISCIII). Budget: 263.750€. 2025-2027. PI: ERNESTO SAMUEL NADAL ALFORJA.
- PID2022-140457OB-I00. Estrés metabólico en cáncer: la respuesta integrada al estrés como diana terapéutica en cáncer de pulmón de célula no pequeña (APOMETALUNG2). Ministerio de Ciencia e Innovación. Budget: 312.500€. 2023-2026. PI: CRISTINA MUÑOZ PINEDO.
- J3M-MC-JZQB. SUNRAY-01, ESTUDIO PIVOTAL INTERNACIONAL EN PARTICIPANTES CON CÁNCER DE PULMÓN NO MICROCÍTICO LOCALMENTE AVANZADO O METASTÁSICO CON MUTACIÓN EN KRAS G12C PARA COMPARAR EL TRATAMIENTO DE PRIMERA LÍNEA CON LY3537982 Y PEMBROLIZUMAB FRENTE A PLACEBO Y PEMBROLIZUMAB EN PACIENTES CON EXPRESIÓN DE PD-L1 ≥50% O CON LY3537982 Y PEMBROLIZUMAB, PEMETREXED, PLATINO FRENTE A PLACEBO Y PEMBROLIZUMAB, PEMETREXED, PLATINO CON INDEPENDENCIA DE LA EXPRESIÓN DE PD-L1. Lilly S.A.. Budget: 172.272€. 2024- . PI: ERNESTO SAMUEL NADAL ALFORJA.
- IVY-P3-24-021. A PHASE 3, OPEN-LABEL, RANDOMIZED 2-ARM STUDY COMPARING THE CLINICAL EFFICACY AND SAFETY OF NIRAPARIB WITH TEMOZOLOMIDE IN ADULT PARTICIPANTS WITH NEWLY-DIAGNOSED, MGMT UNMETHYLATED GLIOBLASTOMA. NeuroTrials, LLC. Budget: 167.986,14€. 2025- . PI: NOELIA VILARIÑO QUINTELA.
- DS7300-188. A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF IFINATAMAB DERUXTECAN (I-DXD), A B7-H3 ANTIBODY DRUG CONJUGATE (ADC), VERSUS TREATMENT OF PHYSICIAN’S CHOICE (TPC) IN SUBJECTS WITH RELAPSED SMALL CELL LUNG CANCER (SCLC) (IDEATE-LUNG02). Daiichi Sankyo, Inc.. Budget: 82.855€. 2024- . PI: MARIA JOVE CASULLERAS.